Selek Alev, Cetinarslan Berrin, Tarkun Ilhan, Canturk Zeynep, Ustuner Berna, Akyay Zeynep
Department of Endocrinology and Metabolism, Faculty of Medicine, Kocaeli University, Umuttepe Kocaeli, 41380, Turkey.
Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Umuttepe Kocaeli, Turkey.
Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1677-1681. doi: 10.1007/s00405-016-4414-6. Epub 2016 Dec 8.
The incidence of thyroid cancer has been greatly increasing. Several studies aimed to investigate biomarkers for prediction of thyroid cancer. Some of these studies have suggested that thyroid autoantibodies (TAb) could be used as predictors of thyroid cancer risk, but the correlation between TAb and PTC is still a matter of debate. The aim of this study is to evaluate thyroid autoimmunity and TAbs in patients with PTC and benign multinodular goiter (MNG) to investigate if TAbs and autoimmune thyroid disease (ATD) could predict thyroid malignancy. A total of 577 patients with thyroid papillary carcinoma (PTC) and 293 patients with benign MNG disease were enrolled postoperatively. Demographic features, thyroglobulin (TgAb) and thyroid peroxidase antibodies (TPOAb) and histologic outcome of the patients were evaluated. The prevalence of ATD and TgAb or TPOAb measurements was not statistically different in PTC and MNG groups. However, tumors were significantly smaller and tumor capsule invasion was seen less frequently in patients with PTC and ATD than without ATD. Patients without ATD had more advanced stage (TNM stage III/IV) tumors than with ATD. Only one of the 11 patients with distant organ metastasis had ATD. The present study demonstrated that the prevalence of ATD diagnosed even with histology or TAb positivity was not different in patients with PTC and MNG. However, having ATD might be associated with a better prognosis in PTC patients.
甲状腺癌的发病率一直在大幅上升。多项研究旨在探究预测甲状腺癌的生物标志物。其中一些研究表明,甲状腺自身抗体(TAb)可作为甲状腺癌风险的预测指标,但TAb与甲状腺乳头状癌(PTC)之间的相关性仍存在争议。本研究的目的是评估PTC患者和良性结节性甲状腺肿(MNG)患者的甲状腺自身免疫和TAb,以研究TAb和自身免疫性甲状腺疾病(ATD)是否能预测甲状腺恶性肿瘤。术后共纳入577例甲状腺乳头状癌(PTC)患者和293例良性MNG疾病患者。评估了患者的人口统计学特征、甲状腺球蛋白抗体(TgAb)、甲状腺过氧化物酶抗体(TPOAb)及组织学结果。PTC组和MNG组中ATD的患病率以及TgAb或TPOAb的检测结果在统计学上无差异。然而,与无ATD的PTC患者相比,有ATD的患者肿瘤明显更小,肿瘤包膜侵犯的发生率更低。无ATD的患者比有ATD的患者肿瘤分期更晚(TNM分期III/IV期)。11例发生远处器官转移的患者中只有1例有ATD。本研究表明,即使通过组织学或TAb阳性诊断出的ATD患病率,在PTC患者和MNG患者中并无差异。然而,患有ATD可能与PTC患者更好的预后相关。